[1]程燕,何启胜.血清miR-451a、 miR-25-3p、GAS8-AS1联合 检测用于早期甲状腺乳头状癌的诊断[J].国际内分泌代谢杂志,2020,40(05):300-303.[doi:10.3760/cma.j.cn121383-20200306-03016]
　Cheng Yan,He Qisheng. Department of Endocrinology,Chizhou People's Hospital,et al.Diagnosis of early papillary thyroid carcinoma by combined detection of serum miR-451a, miR-25-3p, and GAS8-AS1[J].International Journal of Endocrinology and Metabolism,2020,40(05):300-303.[doi:10.3760/cma.j.cn121383-20200306-03016]
点击复制

血清miR-451a、 miR-25-3p、GAS8-AS1联合 检测用于早期甲状腺乳头状癌的诊断()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年05期
页码:
300-303
栏目:
论著
出版日期:
2020-09-20

文章信息/Info

Title:
Diagnosis of early papillary thyroid carcinoma by combined detection of serum miR-451a, miR-25-3p, and GAS8-AS1
作者:
程燕; 何启胜
池州市人民医院内分泌科 247000
Author(s):
Cheng Yan;  He Qisheng. Department of Endocrinology;  Chizhou People's Hospital;  Chizhou 247000;  China Corresponding author: Cheng Yan;  Email:1390482547@qq.com
Department of Endocrinology, Chizhou People's Hospital, Chizhou 247000, China Corresponding author: Cheng Yan, Email:1390482547@qq.com
关键词:
miRNA-451a;  GAS8-AS1;  miRNA-25-3p;  甲状腺乳头状癌;  诊断
Keywords:
miRNA-451a;  GAS8-AS1;  miRNA-25-3p;  Papillary thyroid carcinoma;  Diagnosis
DOI:
10.3760/cma.j.cn121383-20200306-03016
文献标志码:
A
摘要:
目的 探讨血清miR-451a、 miR-25-3p、GAS8-AS1联合用于早期甲状腺乳头状癌的诊断价值。方法 纳入2016年3月至2019年3月池州市人民医院收治的早期甲状腺乳头状癌患者70例为肿瘤组、良性结节患者70例为良性组、健康体检者70名为对照组。通过实时荧光定量PCR检测血清miR-451a、miR-25-3p、GAS8-AS1的表达量。通过酶联免疫吸附试验检测患者血清甲状腺球蛋白(Tg)水平。用受试者工作特征(ROC)曲线的曲线下面积(AUC)分析miR-451a、miR-25-3p、GAS8-AS1检测在早期甲状腺乳头状癌中的诊断意义。结果 肿瘤组、良性组和对照组血清miR-451a、miR-25-3p、GAS8-AS1、Tg的表达水平差异存在统计学意义(F=14.920、9.849、15.060、9.090,P均<0.05)。血清miR-451a、miR-25-3p、 GAS8-AS1、Tg鉴别肿瘤组和对照组的敏感性分别为86%、83%、87%、83%,特异性分别为93%、83%、87%、73%,鉴别肿瘤组和良性组的敏感性分别为97%、97%、78%、84%,特异性分别为87%、80%、93%、71%。miR-451a、miR-25-3p、GAS8-AS1联合对早期甲状腺乳头状癌诊断的敏感性为94.29%,特异性为88.57%,准确性为90.48%。结论 血清miR-451a、 miR-25-3p、GAS8-AS1联合检测可能在诊断早期甲状腺乳头状癌中具有一定价值。
Abstract:
Objective To investigate the diagnostic value of combined detection of serum miR-451a, miR-25-3p and GAS8-AS1 in early thyroid papillary carcinoma.Methods A total of 70 patients with early thyroid papillary carcinoma admitted to Chizhou People's Hospital from March 2016 to March 2019 were included in the tumor group, 70 patients with benign nodules were included in the benign group, and 70 healthy people were included in the control group. The expressions of serum miR-451a, miR-25-3p and GAS8-AS1 were detected by real-time fluorescent quantitative PCR. Serum thyroglobulin(Tg)was detected by enzyme-linked immunosorbent assay. The diagnostic significance of detection of miR-451a, miR-25-3p and GAS8-AS1 in early thyroid papillary carcinoma was analyzed with the area under curve(AUC)of receiver operating characteristic(ROC)curve.Results Serum levels of miR-451a, miR-25-3p, GAS8-AS1 and Tg in tumor group, benign group and control group were significantly different(F=14.920, 9.849, 15.060, 9.090, all P<0.05). The sensitivity of serum miR-451a, miR-25-3p, GAS8-AS1 and Tg to identify the tumor group and the control group were 86%, 83%, 87%, 83%, and the specificity were 93%, 83%, 87%, 73%, respectively. The sensitivity to identify the tumor group and the benign group were 97%, 97%, 78%, 84%, and the specificity were 87%, 80%, 93%, 71%, respectively. Combination of serum miR-451a, miR-25-3p, and GAS8-AS1 in the diagnosis of early thyroid papillary carcinoma showed a sensitivity of 94.29%, specificity of 88.57%, and accuracy of 90.48%.Conclusion Combined detection of serum levels of miR-451a, miR-25-3p and GAS8-AS1 can be used as potential markers for the diagnosis of early thyroid papillary carcinoma.

参考文献/References:

[1] Ma L, Zhou Y, Luo X, et al. Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer[J].Oncotarget,2017,8(3):4125-4135.DOI:10.18632/oncotarget.13670.
[2] Min L, Qinbin S, Hang L, et al. Circulating miR-25-3p and miR-451a may be potential biomarkers for the diagnosis of papillary thyroid carcinoma[J].PLOS One,2015,10(7):e0132403.DOI:10.1371/journal.pone.0132403.
[3] Dongxue Z, Xin L, Bojun W, et al. Plasma lncRNA GAS8-AS1 as a potential biomarker of papillary thyroid carcinoma in Chinese patients[J].Int J Endocrinol,2017,2017:2645904.DOI:10.1155/2017/2645904.
[4] 张渊琪, 赵德善. 分化型甲状腺癌的治疗进展[J]. 国际放射医学核医学杂志, 2017, 41(2):126-131.DOI:10.3760/j.issn:1673-0860.2006.06.028.
[5] Mallick UK. The revised American Thyroid Association management guidelines 2009 for patients with differentiated thyroid cancer: an evidence-based risk-adapted approach[J].Clin Oncol(R Coll Radiol), 2010, 22(6):472-474.DOI: 10.1016/j.clon.2010.05.001.
[6] Wang Z, Zhang H, Zhang P, et al. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis[J].Med Oncol, 2013, 30(2):577.DOI:10.1007/s12032-013-0577-9.
[7] Esposito F, Tornincasa M, Pallante P, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2[J].J Clin Endocrinol Metab, 2012,97(5):E710-E718.DOI:10.1210/jc.2011-3068.
[8] 罗雪兰, 陈伟, 莫国君,等. 27-nt miRNA对血管内皮细胞eNOS表达/活性的调节及其代谢产物的影响[J]. 现代生物医学进展, 2017,17(8):1442-1447.DOI:10.13241/j.cnki.pmb.2017.08.009.
[9] Pan W, Zhou L, Ge M, et al. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations[J].Hum Mol Genet,2016,25(9):1875.DOI:10.1093/hmg/ddw056.
[10] Pan W, Zhou L, Ge M, et al. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations[J].Hum Mol Genet, 2016,25(9):1875-1884.DOI:10.1093/hmg/ddw056.
[11] Pan W, Zhang N, Liu W, et al. The long noncoding RNA GAS8-AS1, suppresses hepatocarcinogenesis by epigenetically activating the tumor suppressor GAS8[J].J Biol Chem, 2018,293(44):17154-17165.DOI:10.1074/jbc.RA118.003055.

备注/Memo

备注/Memo:
通信作者:程燕,Email:1390482547@qq.com
更新日期/Last Update: 2020-09-20